Torrent Pharmaceuticals Q1 Results: Net profit up 3% YoY to ₹566 crore
Torrent Pharmaceuticals posted a 55% revenue jump to ₹4,921 crore in Q1FY27, driven by the JB Pharma merger and strong India sales. Net profit rose 3% to ₹566 crore, with operational EBITDA surging 61% to ₹1,664 crore. Exceptional items of ₹21 crore, including a warehouse fire write-off, impacted the final profit figure.
*this image is generated using AI for illustrative purposes only.
Torrent Pharmaceuticals reported a consolidated net profit of ₹566 crore for the quarter ended June 30, 2026, marking a 3% increase from ₹548 crore in the same period last year. Consolidated revenue from operations jumped 55% year-on-year to ₹4,921 crore, significantly boosted by the inclusion of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) following its amalgamation with effect from January 21, 2026. The company’s operational EBITDA rose 61% to ₹1,664 crore, maintaining a margin of 33.8%. The Board of Directors approved the unaudited standalone and consolidated financial results on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The statutory auditors, B S R & Co. LLP, issued a limited review report on the financial statements pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations. The audit concluded that nothing came to their attention to cause them to believe that the statement had not disclosed all required information or contained any material misstatement. The comparative figures for the quarter and year ended March 31, 2026, have been restated to reflect the pooling of interest method accounting for the JB Pharma merger, as approved by the National Company Law Tribunal (NCLT) on July 6, 2026.
Financial Performance Breakdown
The consolidated revenue surge was underpinned by robust performance across both the base business and the newly integrated JB Pharma segment. The base business generated revenues of ₹3,720 crore, representing a 17% organic growth year-on-year. The JB Pharma segment contributed ₹1,201 crore, up 10% compared to the prior year’s corresponding period. Standalone revenue reached ₹4,158 crore, up from ₹2,616 crore in Q1FY26, with standalone net profit standing at ₹492 crore.
| Metric | Q1FY27 (Consolidated) | Q1FY26 (Consolidated) | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹4,921 crore | ₹3,178 crore | 55% |
| Operational EBITDA* | ₹1,664 crore | ₹1,032 crore | 61% |
| EBITDA Margin | 33.8% | 32.5% | +130 bps |
| Net Profit After Tax | ₹566 crore | ₹548 crore | 3% |
| Gross Margin | 76.4% | 75.6% | +80 bps |
*Before exceptional items
Exceptional items impacted the bottom line by ₹21 crore in Q1FY27. This included ₹2 crore towards regulatory and statutory fees associated with the JB Pharma acquisition, and a ₹19 crore inventory write-off due to a fire incident at an erstwhile JB Pharma warehouse. The company noted that no effect has been given to the related insurance claim, which remains under assessment. Additionally, severance compensation of ₹19 crore was recorded in the previous fiscal year related to the restructuring of JB Pharma’s distribution network.
Regional Business Highlights
The India business delivered record high organic growth, with revenues reaching ₹2,157 crore, up 19% year-on-year against an IPM market growth of 12%. Torrent secured the top rank in the Indian cardiac market and saw its generic Semaglutide product achieve a 36% market share in Q1FY27. Internationally, US revenues grew 36% to ₹418 crore, driven by new launches. Brazil revenues increased 27% to ₹277 crore, although the company undertook a one-time channel inventory reduction due to credit period requests amid rising interest costs. Germany revenues remained flat at ₹318 crore, impacted by supply disruptions.
What the Numbers Show
The significant divergence between the 55% revenue growth and the modest 3% net profit growth highlights the capital-intensive nature of the recent expansion. While operational efficiency improved with EBITDA margins expanding by 130 basis points to 33.8%, the integration costs and exceptional items dampened the bottom-line impact. The debt equity ratio stood at 0.82 times for the consolidated entity, reflecting the substantial leverage taken to fund the JB Pharma acquisition. However, the debt service coverage ratio remains healthy at 3.98 times, indicating sufficient cash flow to meet debt obligations despite the increased borrowings.
Historical Stock Returns for Torrent Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.13% | -3.20% | +4.61% | +23.97% | +29.30% | +220.81% |
How will the ₹19 crore inventory write-off from the JB Pharma warehouse fire impact future cash flows, and what is the expected timeline for the insurance claim resolution?
What specific integration synergies does Torrent Pharmaceuticals expect to realize in the next 12-24 months to offset the high debt equity ratio of 0.82x incurred for the JB Pharma acquisition?
Given the flat revenue performance in Germany due to supply disruptions, what corrective supply chain measures are being implemented to stabilize European operations?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
